Press "Enter" to skip to content

FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

The FDA granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

Original source: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm626710.htm

Also Read:   2019 Safety Communications